JP2026500231A - がんをスクリーニングおよび診断するためのスコアを生成するためのｋｒｔ１９およびｃｏｌ１ａ２の発現レベルの組み合わせ - Google Patents

がんをスクリーニングおよび診断するためのスコアを生成するためのｋｒｔ１９およびｃｏｌ１ａ２の発現レベルの組み合わせ

Info

Publication number
JP2026500231A
JP2026500231A JP2025533472A JP2025533472A JP2026500231A JP 2026500231 A JP2026500231 A JP 2026500231A JP 2025533472 A JP2025533472 A JP 2025533472A JP 2025533472 A JP2025533472 A JP 2025533472A JP 2026500231 A JP2026500231 A JP 2026500231A
Authority
JP
Japan
Prior art keywords
krt19
col1a2
tumor
subject
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025533472A
Other languages
English (en)
Japanese (ja)
Inventor
ブエラ、ラウレアノ シモン
オルマエチェ、サイオア ドミンゲス
ロペス、アンヘル コンチャ
アレン、ベゴーニャ オテロ
ペレス、ララ ソフィア エステヴェス
アレン、マリア オテロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncomatryx Biopharma SL
Original Assignee
Oncomatryx Biopharma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomatryx Biopharma SL filed Critical Oncomatryx Biopharma SL
Publication of JP2026500231A publication Critical patent/JP2026500231A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
JP2025533472A 2022-12-07 2023-12-06 がんをスクリーニングおよび診断するためのスコアを生成するためのｋｒｔ１９およびｃｏｌ１ａ２の発現レベルの組み合わせ Pending JP2026500231A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22383195.9 2022-12-07
EP22383195.9A EP4382911B1 (en) 2022-12-07 2022-12-07 Combining the expression levels of krt19 and col1a2 to produce a score for screening and diagnosing cancer
PCT/EP2023/084627 WO2024121272A1 (en) 2022-12-07 2023-12-06 Combining the expression levels of krt19 and col1a2 to produce a score for screening and diagnosing cancer

Publications (1)

Publication Number Publication Date
JP2026500231A true JP2026500231A (ja) 2026-01-06

Family

ID=84463216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025533472A Pending JP2026500231A (ja) 2022-12-07 2023-12-06 がんをスクリーニングおよび診断するためのスコアを生成するためのｋｒｔ１９およびｃｏｌ１ａ２の発現レベルの組み合わせ

Country Status (7)

Country Link
EP (1) EP4382911B1 (enExample)
JP (1) JP2026500231A (enExample)
KR (1) KR20250118849A (enExample)
CN (1) CN120344855A (enExample)
AU (1) AU2023389133A1 (enExample)
ES (1) ES3066049T3 (enExample)
WO (1) WO2024121272A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1631689A2 (en) * 2003-05-28 2006-03-08 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP3426797A1 (en) * 2016-03-09 2019-01-16 Myriad International GmbH Method for determining the risk of recurrence of an estrogen receptor-positive and her2-negative primary mammary carcinoma under an endocrine therapy

Also Published As

Publication number Publication date
WO2024121272A1 (en) 2024-06-13
CN120344855A (zh) 2025-07-18
EP4382911C0 (en) 2026-01-28
KR20250118849A (ko) 2025-08-06
AU2023389133A1 (en) 2025-07-03
ES3066049T3 (enExample) 2026-05-11
EP4382911A1 (en) 2024-06-12
EP4382911B1 (en) 2026-01-28

Similar Documents

Publication Publication Date Title
Huang et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer
Abdipourbozorgbaghi et al. Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC)
Agell et al. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression
Zhang et al. Circulating microRNA 216 as a marker for the early identification of severe acute pancreatitis
Zhang et al. Telomerase-positive circulating tumor cells are associated with poor prognosis via a neutrophil-mediated inflammatory immune environment in glioma
Noro et al. A two-gene prognostic classifier for early-stage lung squamous cell carcinoma in multiple large-scale and geographically diverse cohorts
RS59161B1 (sr) Mikro-rnk biomarkeri za identifikovanje rizika i/ili dijagnostikovanje tumora pluća
EP3788167A1 (en) Methods of diagnosing and treating patients with cutaneous squamous cell carcinoma
Tombolan et al. Circulating miR-26a as potential prognostic biomarkers in pediatric rhabdomyosarcoma
Sun et al. Predictive nomogram of the clinical outcomes of colorectal cancer based on methylated SEPT9 and intratumoral IL-10+ Tregs infiltration
CA3177987A1 (en) Methods for identifying a medical condition in a human subject
JP6143920B1 (ja) 卵巣がんの予後診断マーカーとしてのｍｍｐ１遺伝子転写産物と検査法
Roberts et al. Prostate-based biofluids for the detection of prostate cancer: A comparative study of the diagnostic performance of cell-sourced RNA biomarkers
Wang et al. Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals MMP mediated expression patterns by distinct tumor microenvironment immune profiles in cervical cancer
EP3446122B1 (en) Marker genes for colorectal cancer classification, method for judging lymph node metastasis for prognosis of colorectal cancer and kit therefor
EP4382911B1 (en) Combining the expression levels of krt19 and col1a2 to produce a score for screening and diagnosing cancer
Zou et al. Circulating miR-326 could serve as a predictive biomarker for response to neoadjuvant chemotherapy in locally advanced cervical cancer
Bender et al. LASSO logistic regression reveals a mixed MiRNA and serum-marker classifier for prediction of immunotherapy response in liquid biopsies of melanoma patients
US11976330B2 (en) MiRNA signature expression in cancer
CN111315897A (zh) 用于黑素瘤检测的方法
CN101522912B (zh) 舌癌的判定方法
Abd El Gayed et al. Evaluation of miRNA 130a-3P and miRNA 301a-3P in Egyptian patients with urinary bladder carcinoma
Chou et al. Application of CTC-derived spheroid for drug screening toward personalized treatment in patients with breast cancer
RU2823255C1 (ru) Способ прогнозирования рецидива рака щитовидной железы после радикального хирургического вмешательства
Kim et al. Quantitative measurement of circulating lymphoidspecific helicase (HELLS) gene transcript: a potential serum biomarker for melanoma metastasis